1Wang M,Zhou Y,Zhang L,et al.Use of bortezomib in B-cell non-Hodgkin's lymphoma.Expert Rev Anticancer Ther,2006,6(7):983-991.
2Orlowski RZ,Voorhees PM,Garcia RA,et al.Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.Blood,2005,105 (8):3058-3065.
3Adams J,Palombella VJ,Sausville EA,et al.Proteasome inhibitors:a novel class of potent and effective antitumor agents.Cancer Research,59(11):2615-2622.
4Leonard JP,Furman RR,Coleman M.Proteasome inhibition with bortezomib:a new therapeutic strategy for non-Hodgkin's lymphoma.Int J Cancer,2006,119(5):971-979.
5Goy A,Younes A,McLaughlin P,et al.Phase Ⅱ study of proteasome inhibitor bortezomib in relapsed or refractory B-cell nonHodgkin's lymphoma.J Clin Oncol,2005,23(4):667-668.
6Mitsiades N,Mitsiades CS,Richardson PG,et al.The porteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents:therapeutic applications.Blood.101 (6):2377-2380.
